type natriuretic peptide (BNP) is a peptide hormone of myocardial origin with significant cardioprotective properties. Patients with myocardial ischemia present with high levels of BNP in plasma and elevated expression in the myocardium. However, the molecular mechanisms of BNP induction in the ischemic myocardium are not well understood. The aim of the investigation was to assess whether myocardial hypoxia induces the production of BNP in human ventricular myocytes. To test the hypothesis that reduced oxygen tension can directly stimulate BNP gene expression and release in the absence of hemodynamic or neurohormonal stimuli, we used an in vitro model system of cultured human ventricular myocytes (AC16 cells). Cells were cultured under normoxic (21% O2) or hypoxic (5% O2) conditions for up to 48 h. The accumulation of BNP, atrial natriuretic peptide (ANP), and vascular endothelial growth factor (VEGF) was then measured. Hypoxia stimulated the protein release of BNP and VEGF but not ANP. In concordance, the increased mRNA levels of BNP and VEGF but not ANP were found on culturing AC16 cells under hypoxic conditions. The analysis of the transcriptional activity of the hypoxia-inducible factor 1 (HIF-1) in nuclear extracts showed that HIF-1 activity was induced under hypoxic conditions. Finally, the treatment of AC16 cells with the HIF-1 inhibitor rotenone in hypoxia inhibited BNP and VEGF release. In conclusion, these data indicate that hypoxia induces the synthesis and secretion of BNP in human ventricular myocytes, likely through HIF-1-enhanced transcriptional activity.
B-type natriuretic peptides; hypoxia-inducible factor 1; myocardial ischemia; heart failure; vascular endothelial growth factor B-TYPE NATRIURETIC PEPTIDE (BNP) is an endogenous substance belonging to the natriuretic isopeptide family. It is mainly synthesized in the ventricular myocardium (32, 40) and plays an important role in body fluid homeostasis as well as in the regulation of blood pressure (26) . In addition, BNP possesses antihypertrophic and antifibrotic properties, conferring it with powerful cardioprotective effects (32) .
Several clinical studies have recently demonstrated the existence of a direct relationship between disease severity and the circulating levels of BNP in patients with heart failure (HF) (8, 25) . This is not surprising, taking into account that myocardial stretching has been demonstrated to be the major stimulus for BNP release by cardiomyocytes (19) , which, in turn, has laid the rationale for the increasing use of BNP levels as a diagnostic and prognostic marker in HF (6, 38) . However, there is growing evidence indicating that an impaired oxygen availability in myocardial cells could also be a specific inducer of BNP synthesis and release. Arguments in favor of this hypothesis include recent findings showing increased plasma levels of BNP in ischemic patients regardless of whether they have normal or impaired left ventricular ejection fraction (13, 28) . On the other hand, an increased gene expression of BNP has been found in heart preparations of rats and pigs exposed to hypoxia (14, 31, 36) and the activation of hypoxia-inducible factor 1␣ (HIF-1␣) has been observed in the myocardium of rats exposed to hypoxia or undergoing coronary artery ligation (17) . Nevertheless, a direct regulatory effect of cardiac hypoxia on BNP synthesis and release in human ventricular cardiomyocytes, as well as the molecular mechanisms involved in this phenomenon, has not been completely established. This is likely due to difficulties in differentiating the hypoxic stimulus from the concomitant effects of other known inducers of BNP production (i.e., hemodynamic changes, myocyte stretching, and neurohormonal stimulus) when the experimental setting is conducted in in vivo and ex vivo preparations. Moreover, the availability of human ventricular cardiomyocytes cell lines is limited because cultures of cardiac tissue have a finite life span in vitro.
In the current study we used an in vitro model system of cultured human ventricular myocytes (AC16 cells) (7) to test the hypothesis of whether reduced oxygen tension can directly stimulate BNP production in the absence of hemodynamic or neurohormonal stimuli. Our results demonstrate that hypoxia directly enhances the synthesis and secretion of BNP in AC16 cells, through a HIF-1␣-dependent mechanism. These results indicate that myocardial hypoxia likely contributes to the increased BNP levels in patients with myocardial ischemia and further support the use of BNP levels as a surrogate biomarker of ischemic heart disease.
MATERIALS AND METHODS
Cell culture. AC16 cells were generated from primary human ventricular cardiomyocytes, as previously described (7) . This immortalized, stable cell line can be repeatedly frozen, thawed, and propagated. Cells were seeded (1 ϫ 10 6 cells/well) in gelatin-coated six-well plates and grown to confluence for 36 h in Dulbecco's modified Eagle's medium (DMEM-F-12), supplemented with 12.5% fetal calf serum, 50 U/ml penicillin, and 50 g/ml streptomycin. Thereafter, the cells were switched to serum-free DMEM-F12 for 10 h and subsequently incubated (37°C) at variable time intervals in DMEM-F12 containing 0.1 mg/ml of bovine serum albumin under normoxic (21% O 2-5% CO2-74% N2) or hypoxic (5% O 2-5% CO2,-90% N2) conditions in a controlled O2 waterjacketed CO 2 incubator (Forma Scientific Series II, 3131, Marietta, OH). When indicated, the cell culture medium also contained the HIF-1 inhibitor rotenone (2.5 M) or vehicle (0.001% DMSO in cell culture medium). Cell bioavailability was assessed on AC16 cells under hypoxic or normoxic conditions cultured for up to 48 h by adding 0.4 mg of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, St. Louis, MO) and incubated at 37°C during 90 min. The media was discarded, and 200 l of N-propanol was added to each well. After 5-10 min of reaction, 50 l of the solution was taken from each well and transferred into a 96-well plate and the optical density was measured at 570 nm (SpectraMax 340, Molecular Devices, Sunnyvale, CA).
Effect of hypoxia on natriuretic peptides and VEGF production in AC16 cells. Following cell culture under normoxic or hypoxic conditions, culture medium samples were obtained on completing the incubation period to measure atrial natriuretic peptide (ANP), BNP, and VEGF. Samples were centrifuged (2,000 rpm, 4°C) and frozen at Ϫ20°C until further analysis. ANP extracted from cell culture medium on Sep Pack C-18 cartridges from Waters Associates (Milford, MA) was measured by radioimmunoassay (Euro-Diagnostica, Arnhem, The Netherlands). BNP was measured using a chemiluminometric immunoassay run on the ADVIA Centaur Immunochemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY). VEGF was measured by enzyme-linked immunosorbent assay (Quantikine, Immunoassay, R&D Systems, Minneapolis, MN) (16, 30) . Eight independent measurements were performed for BNP and ANP at each time point. Six independent measurements were performed for VEGF.
Hypoxia-induced messenger RNA expression in AC16 cells. Total RNA was extracted from AC16 cells cultured under normoxic or hypoxic conditions using a commercially available kit (RNeasy, Qiagen). All samples were DNAse treated before transcription using the TURBO DNA-free kit (Ambion, Austin, TX), and the RNA concentration was determined by spectrophotometric analysis (ND-100 Spectrophotometer, Nanodrop Technology). DNase-treated total RNA (1 g) was reverse transcribed (RT) using a complementary DNA synthesis kit (High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA). Primers for BNP (left, 5Ј-gatggtgcaagggtctgg-3Ј; and right, 5Ј-cctcttaatgccgcctca-3Ј), VEGF-A (left, 5Ј-gcagcttgagttaaacgaacg-3Ј; and right, 5Ј-ggttcccgaaaccctgag-3Ј), ANP (left, 5Ј-gagcggactgggctgtaac-3Ј; and right, 5Ј-ggagcctcttgcagtctgtc-3Ј), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as an endogenous standard (left, 5Ј-agccacatcgctcagacac-3Ј; and right, 5Ј-cgcccaatacgaccaaat-3Ј) were designed according to human BNP, VEGF-A, ANP, and GAPDH sequences (GenBank accession numbers NM_002521, NM_001025366, NM_006172, and NM_002046, respectively). The primers and probes used for the different genes studied were designed to include intron spanning using the Universal Probe Library Assay Design Center (Roche Applied Science, http://www.roche-appliedscience.com/sis/rtpcr/upl/adc.jsp). Real-time quantitative PCR was performed in duplicate and analyzed with Opticon 2 (MJ Research, Capital Court, Reno, NV). Total volume reaction (20 l) of diluted 1:16 cDNA, 200 nM primer dilution, 100 nM prevalidated 9-mer probe (Universal ProbeLibrary, Roche Diagnostics), and FastStart TaqMan Probe Master (Roche Diagnostics) was used in each PCR reaction. The fluorescence signal was captured during each of the 45 cycles (denaturizing 10 s at 95°C, annealing 30 s at 60°C, and extension 30 s at 72°C). GAPDH was used as the reference gene for normalization, and water was used as the negative control. The relative quantification was calculated using the comparative threshold cycle (CT), which is inversely related to the abundance of mRNA in the initial sample. The mean CT of duplicate measurements was used to calculate ⌬CT as the difference in CT for the target and reference. The relative quantity of product was expressed as the fold induction of the target gene compared with the reference gene according to the formula 2 Ϫ⌬⌬CT , where ⌬⌬C T represents ⌬CT values normalized with the mean ⌬CT of basal samples. Eight independent measurements were performed at each time point.
Effect of hypoxia on HIF-1 activation in AC16 cells. The intranuclear activity of HIF-1 was determined in nuclear extracts of AC16 cells obtained following hypoxic or normoxic exposure using a nuclear extract kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions. The cells were collected and lysed, and the cytosolic fraction was removed. The nuclear pellets were homogenized, and the nuclear extracts were collected. The protein concentration in the nuclear extracts was determined using the Bradford assay (1). The activation of HIF-1 was quantified using a TransAM kit (Active Motif), which measures binding to a 26-bp hypoxia response element oligonucleotide from the erythropoietin gene attached to a 96-well plate (22) . Nuclear extract (6 g) were used per sample. Nuclear extracts from COS-7 cells treated with the HIF-1␣-stabilizer CoCl 2, which were provided with the kit, were used as positive control. CoCl2 prevents HIF-1␣ ubiquitinization and degradation in addition to inducing its expression (37) . Nuclear extracts incubated with an HIF-1-specific competitor oligonucleotide served as a negative control. To assess the effect of inhibiting HIF-1 activation, the AC16 cells were exposed to rotenone (2.5 M), an inhibitor of hypoxic HIF-1␣ stabilization (21), for 40 min, followed by an exposure to hypoxia (5% O 2) or normoxia (21% O2) for 1, 3, 6, and 24 h. Thereafter, HIF-1 activity was determined and the medium was collected for further determination of VEGF and BNP concentrations as described in Effect of hypoxia on natriuretic peptides and VEGF production in AC16 cells. Eight independent measurements were performed at each time point.
Statistical analysis. The experimental data are presented as means Ϯ SE from at least six independent experiments. The timecourse production of natriuretic peptides and VEGF under hypoxic and normoxic conditions was analyzed by one-way analysis of variance and post hoc Bonferroni t-test. Comparisons between normoxic and hypoxic conditions in the same time conditions were performed with the unpaired Student's t-test. This test was also used to compare the effect of rotenone on BNP and VEGF production under hypoxic conditions in AC16 cells. Differences were considered significant at a value of P Ͻ 0.05.
RESULTS

Hypoxia increases BNP production in AC16 cells.
To investigate whether reduced oxygen tension could be a specific stimulus for BNP secretion in human cardiomyocytes, we incubated AC16 cells under hypoxic conditions for increasing time periods and the BNP concentration in the cell culture medium was assessed. We also measured AC16 secretion of ANP, another member of the natriuretic isopeptide family produced by the human heart. AC16 cells time-dependently increased BNP levels within the 48-h incubation period. Moreover, the secretion of this peptide was significantly higher at 12, 24 and 48 h of hypoxic exposure than under normoxic conditions (Fig. 1) . In fact, BNP levels in the media of hypoxic cells were two-to threefold higher than those in normoxic cells. By contrast, the secretion of ANP was almost negligible and did not experience any modification due to hypoxic exposure for up to 48 h (Fig. 1) . The hypoxic induction of BNP was accompanied by a parallel augmentation of the known hypoxia-sensitive factor VEGF (Fig. 1) . The kinetics of VEGF production significantly differ in normoxic or hypoxic AC16 cells. The levels of VEGF in the media of cells cultured at 5% O 2 were between 1.5 to 2.5-fold higher than in the media of 21% O 2 AC16 cells. No differences in cell viability, as assessed by the MTT assay, were observed between normoxic or hypoxic cells. Cell viability after the incubation of AC16 cells for 48 h in normoxic or hypoxic conditions was 101 Ϯ 6% and 101 Ϯ 3%, respectively.
Hypoxia increases the messenger expression of VEGF and BNP in AC16 cells. To determine whether the increased BNP release during hypoxic exposure was accompanied by an induction of BNP mRNA, we harvested the cells from the same plates for the measurement of BNP gene expression. GAPDH was used as an endogenous control, and no significant differences in GAPDH mRNA expression were found over the experimental periods in both normoxia-and hypoxia-exposed AC16 cells. Real-time PCR analysis indicated that hypoxic exposure resulted in a 2.8-fold increase in BNP mRNA levels within 6 h, with this difference being sustained for up to 12 h under this condition (Fig. 2) . There was a trend toward higher BNP mRNA levels in AC16 cells exposed for to 5% O 2 for 24 h, although the differences did not reach statistical significance. A similar behavior was observed at assessing the pattern expression of VEGF mRNA. Six hours following hypoxic exposure, the AC16 cells showed a fourfold increase in VEGF mRNA compared with normoxic control cells. However, VEGF mRNA levels dropped to normoxic control levels after 12 and 24 h of hypoxic exposure (Fig. 2) . No differences in ANP mRNA expression were found between cells cultured at normoxic or hypoxic conditions at any of the investigated time periods (data not shown).
Hypoxia induces HIF-1 activation in AC16 cells. The time course activation of HIF-1 under hypoxic conditions assessed as HIF-1 DNA binding to a specific hypoxia responsive element oligonucleotide sequence is shown in Fig. 3. Following 1,  3 , and 6 h of hypoxia exposure, AC16 cells showed a 2.0-, 2.4-, and 3.0-fold over normoxic HIF-1 DNA binding, respectively. Hypoxic cells pretreated with rotenone did not increase HIF-1 DNA binding compared with cells exposed to normoxic conditions, indicating that rotenone is able to inhibit HIF-1 DNA binding in hypoxic cells (Fig. 3) .
The inhibition of HIF-1 decreases hypoxia-induced BNP and VEGF production in AC16 cells. Although the data presented in Fig. 4 are consistent with a significant role of HIF-1 in BNP expression, they do not provide direct evidence for its involvement. Therefore, we next sought to determine whether HIF-1 inhibition by rotenone may prevent hypoxic BNP-induced secretion in AC16 cells. The repression of hypoxic VEGF secretion by rotenone was assessed as well. As anticipated, hypoxia resulted in a significant 180% increase in BNP levels in the media of AC16 cells. However, this effect was fully abolished when cardiomyocytes were incubated in the presence of rotenone. The inhibitory action of rotenone on BNP secretion was paralleled by an identical effect on VEGF production (Fig. 4) , indicating that the mechanisms of hypoxia-stimulated BNP and VEGF secretion are mediated by an increased HIF-1 DNA binding.
DISCUSSION
The current study shows that the BNP messenger expression and peptide release by cultured human ventricular myocytes (AC16 cells) is enhanced in response to reduced oxygen tension. When myocytes were exposed to hypoxia, the elevation in BNP secretion was preceded by the augmentation of BNP gene expression, suggesting that the hypoxia-induced alterations in BNP activity were determined at the transcriptional level. The activation of HIF-1 occurred earlier than the elevation of BNP gene expression, and the hypoxic induction of BNP was paralleled by a similar expression pattern and protein secretion of the known HIF-1 target factor VEGF, suggesting a role of the transcription factor HIF-1 in BNP activation by hypoxia. Lastly, hypoxia-induced BNP protein secretion was significantly attenuated by rotenone, a wellknown inhibitor of HIF-1 activation.
At present, it is widely accepted that the elevation of BNP secretion in the ischemic heart is the result of ventricular wall distension secondary to myocardial ischemia (33) . However, there is also increasing evidence suggesting that reduced oxygen availability may directly influence BNP release. This is supported by studies showing that patients presenting with acute myocardial infarction or acute coronary syndromes display transient elevations of BNP (9, 18, 27) . Moreover, it has also been reported that patients with coronary artery disease and normal left ventricular function display an elevation in plasma BNP levels which are associated with increased BNP expression in myocardial tissue (13) . Altogether, these results support the concept that cardiac ischemia enhances BNP release in the absence of myocardial stretch.
It is known that the mRNA expression and protein concentration of BNP are augmented in the failing heart by a mechanism dependent on the stimulation of p38 mitogen-activated protein kinase and the activation of the transcription factor NF-B in the cardiac myocyte (20) . However, the underlying pathophysiological mechanisms of BNP induction in cardiac ischemia have not been identified. Hypoxia is a critical component of the ischemic myocardium, which may explain the changes in BNP expression associated with ischemia. In the current study, we used AC16 ventricular myocytes to determine the mechanisms regulating BNP secretion under reduced oxygen tension. The AC16 cell line is a proliferating human cardiomyocyte cell line derived from nonproliferating primary cultures of adult ventricular heart tissue. The AC16 cell line closely resembles adult human cardiomyocytes with regard to various antigenic determinants, thus constituting a valuable tool for the study of the signaling pathways involved in BNP synthesis and release (7, 29) In particular, we assessed whether hypoxia specifically triggers BNP production in the absence of other known stimuli of BNP such as hemodynamic, neural, and hormonal factors (24) . The effect of hypoxia on VEGF and ANP production by the cardiomyocyte cell line was also evaluated to validate the sensitivity and specificity of the AC16 cells response to hypoxia. VEGF is a well-known hypoxiaresponsive gene (35) , whereas ANP is a cardiac BNP isopep- Fig. 4 . BNP (top) and VEGF (bottom) production after 24 h of normoxic exposure (21% O2), hypoxic exposure (5% O2), and hypoxic and normoxic exposure with the HIF-1 activation inhibitor rotenone (2.5 M). Cells were exposed to rotenone 40 min before normoxia or hypoxia and kept under this condition thereafter. P Ͻ 0.05 vs. 5% O2; n ϭ 8 independent measurements. Fig. 3 . Effect of hypoxia on hypoxia-inducible factor-1 (HIF-1) DNA binding activity in AC16 cells. Cells were incubated for variable time intervals in either normoxia (21% O2) or hypoxia (5% O2) in the presence or in the absence of rotenone (2.5 M). Cells were exposed to rotenone 40 min before hypoxia treatment and kept under this condition thereafter. Following incubation, the cells were lysed and nuclear extracts were tested for DNA binding to a probe containing a hypoxia responsive element sequence. The presence of the DNA-bound transcription factor was then detected by anti-HIF-1␣ antibodies and revealed by colorimetry; n ϭ 8 independent measurements. tide mainly secreted by atrial myocytes that is much less accurate than BNP for the diagnosis of HF (4, 10) .
Cells cultured under hypoxic conditions experienced a significant increase in BNP but not in ANP production. Despite both natriuretic peptides displaying similar physiological mechanisms, this different response following hypoxic stimulation is not surprising. Decreased oxygen tension is a powerful stimulus for ANP production in atrial myocytes (3) but not in ventricular cardiomyocytes. Atrial myocytes are the major source and storage site of ANP, but ventricular myocytes secrete ANP by a constitutive pathway and store only a minor part of the peptide (3) . Contrary to what occurs in the atrial tissue, the lack of stored ANP prevents ventricular cardiocytes from increasing ANP secretion in response to reduced oxygen tension. In contrast, whether hypoxia regulates BNP production in ventricular myocytes, a potentially larger source of BNP, it is still under discussion. Goetze et al. (14) used freshly harvested pig ventricular cells incubated under oxygen-deprived conditions, and their findings suggest an effect of hypoxia on BNP synthesis at the transcriptional level. Furthermore, the hypoxic induction of BNP mRNA has recently been described in cultured adult rat ventricular cardiomyocytes (39) . All these previous investigations corroborate our findings, showing a clear stimulatory effect of hypoxia on BNP secretion in human cardiomyocyte cell lines, and suggest the existence of an oxygen-regulated BNP pathway in these cells. This hypothesis is further supported by our results that show a marked increased VEGF production in AC16 cells cultured under hypoxic conditions. In fact, it is well known that oxygen tension closely regulates the signaling pathways, resulting in an increased VEGF production by different cell types (35) .
The results obtained at assessing messenger expression of BNP, VEGF, and ANP in AC16 cells under hypoxic conditions additionally sustained the concept of an oxygen-mediated regulatory mechanism for BNP release in the human-derived cardiomyocyte cell line. Cells cultured at low oxygen tension contained higher BNP and VEGF mRNA abundance than cells cultured in normoxia, a difference not observed when ANP mRNA was measured. Nevertheless, it should be noted that there is a difference in the expression pattern induced by hypoxia between VEGF and BNP. This discrepancy may underlie differences in posttranslational mechanisms or even in alternative regulatory pathways involved in BNP activation.
HIF-1 is a heterodimeric transcription factor that is considered a crucial mediator of the cellular response found under conditions of diminished free oxygen availability. HIF-1 is composed of an inducibly expressed HIF-1␣ subunit and a constitutively expressed HIF-1␤ subunit. HIF-1␣ is sensitive to hypoxia and is rapidly degraded by the ubiquitin proteasomal pathway under normoxic conditions. Under hypoxic conditions, HIF-1␣ degradation is blocked, thus allowing HIF-1 accumulation and migration to the nucleus, where it plays a key role in the transcriptional activation of the hypoxia-inducible genes such as VEGF by binding to specific hypoxia response elements in their regulatory region (35) . There is evidence that HIF-1 may induce BNP production in cardiomyocytes. Putative HIF-1 binding sites have been identified within the promoter of the BNP gene (23) , and experimental studies have shown that animals exposed to hypoxia display an increased myocardial BNP gene expression (14, 31, 36) . Moreover, the activation of HIF-1␣ has been observed in the ischemic myocardium (17) , and the hypoxic induction of BNP mRNA expression has recently been described through a HIF-1-dependent mechanism in cultured adult rat cardiomyocytes and in different noncardiac human cell lines (39) . In the present study, hypoxic cell cultures depicted enhanced HIF-1␣ activity, a phenomenon that was not seen when the cells were incubated with rotenone, a well-known inhibitor of HIF-1␣ stabilization in hypoxia (12, 21, 34) . Rotenone abolishes the hypoxic stabilization of HIF-1␣ protein by inhibiting mitochondrial complex I activity (34) , likely by blocking the electron flow proximally to complex III, thereby ablating the generation of reactive oxygen species during hypoxia (2). The HIF-1 inhibitor also abolished the enhanced hypoxic production of BNP and VEGF in AC16 cells. These results indicate that the hypoxia-induced increase in BNP and VEGF secretion in AC16 cells is closely related to HIF-1␣ stabilization, further emphasizing the existence of a transcriptionally regulated mechanism for BNP secretion in response to a decreased oxygen tension in human ventricular cardiomyocytes.
It is important to remark, however, the potential limitations of our findings as a consequence of using the AC16 cell line. In fact, the introduction of the SV40 gene allows primary cardiomyocytes to reenter in the cell cycle, thus providing an in vitro model that shows most of the characteristic features of primary human cardiac cells. Nevertheless, the presence of the SV40 gene may also prevent the expression of some phenotypic manifestations of cardiomyocytes, including the loss of organized contractile apparatus, low action potential, or downregulation of transcription factors (7) . This in turn may help to explain the differences between the in vitro results and those obtained in a more clinical scenario. In fact, hypoxia induced a transitory 12-h increase in BNP mRNA expression, but at 24 h in culture, no differences were found between normoxic or hypoxic cells. However, patients with ischemic heart disease present high-circulating levels of BNP (6) , which likely reflect a persistent activation of BNP mRNA in the cardiac tissue. Moreover, beyond the particular characteristic of the in vitro model, other well-known inducers of BNP secretion including neurohormones, cytokines, and growth factors (5) should be taken into account when explaining the differences between in vitro and in vivo findings.
The elevation of BNP in response to myocardial hypoxia may have beneficial endocrine and paracrine effects. BNP is a powerful endogenous natriuretic, diuretic, and vasodilatation peptide that antagonizes the vasoconstrictor activity of the renin-angiotensin-aldosterone system and inhibits the sympathetic nervous system (15, 26) . In addition to the endocrine effects of BNP, there are increasing data pointing to BNP as a paracrine factor exerting cardioprotective functions in the heart, including the regulation of myocyte growth and the inhibition of cardiac fibroblast proliferation and extracellular matrix deposition (11, 32) . Consequently, the observed induction of BNP may constitute a homeostatic mechanism addressed to preserve cardiovascular hemodynamics and prevent fibroproliferative processes in the hypoxic heart.
